Federal Circuit Won't Rehear Celebrex Patent Dispute

Law360, New York (May 07, 2008, 12:00 AM ET) -- A federal appeals court will not revisit its March decision that prevents Teva Pharmaceuticals USA Inc. from launching a generic copy of Pfizer Inc.’s painkiller Celebrex for the next six years.

Both Pfizer and Teva had asked the U.S. Court of Appeals for the Federal Circuit for a rehearing on its split ruling in March that tossed aside one of Pfizer’s three disputed patents on Celebrex while affirming a lower court’s finding that Teva infringed the other two patents, which do not expire until May 2014....
To view the full article, register now.